Phreesia (NYSE:PHR) Shares Gap Up on Strong Earnings

Posted by Brenda Bartman on May 28th, 2026

Phreesia, Inc. (NYSE:PHR – Get Free Report)’s share price gapped up before the market opened on Thursday following a stronger than expected earnings report. The stock had previously closed at $9.13, but opened at $10.78. Phreesia shares last traded at $9.7710, with a volume of 468,672 shares traded.

The company reported $0.05 EPS for the quarter, topping the consensus estimate of $0.02 by $0.03. Phreesia had a return on equity of 3.23% and a net margin of 0.48%.The firm had revenue of $130.94 million for the quarter, compared to the consensus estimate of $130.08 million. During the same quarter last year, the company earned ($0.07) earnings per share. The business’s revenue for the quarter was up 12.9% compared to the same quarter last year.

Key Headlines Impacting Phreesia

Here are the key news stories impacting Phreesia this week:

Positive Sentiment: Phreesia reported fiscal Q1 2027 EPS of $0.05, topping the $0.02 consensus estimate, while revenue of $130.94 million slightly beat expectations and rose 12.9% year over year.
Positive Sentiment: Management guided FY2027 revenue to $510 million-$520 million and kept adjusted EBITDA guidance at $125 million-$135 million, suggesting continued growth and profitability progress.
Neutral Sentiment: Several firms reiterated reminders about the July 13, 2026 lead-plaintiff deadline in the pending class action, keeping legal overhang news in focus for investors.
Negative Sentiment: The newly highlighted class action alleges Phreesia made misleading statements about revenue growth projections and downplayed slowing growth in Network Solutions, which could increase investor concern about future disclosures and litigation risk. Article title

Analyst Upgrades and Downgrades

Several equities analysts have recently commented on PHR shares. Stephens lowered their target price on shares of Phreesia from $32.00 to $20.00 and set an “overweight” rating on the stock in a report on Tuesday, March 31st. Mizuho dropped their target price on Phreesia from $22.00 to $19.00 and set an “outperform” rating for the company in a report on Tuesday, March 24th. Citizens Jmp reaffirmed a “market perform” rating on shares of Phreesia in a research note on Wednesday, April 1st. BMO Capital Markets cut their price objective on Phreesia from $32.00 to $14.00 and set an “outperform” rating on the stock in a research report on Tuesday, March 31st. Finally, Truist Financial restated a “hold” rating and issued a $11.00 target price (down from $24.00) on shares of Phreesia in a research note on Tuesday, March 31st. Ten research analysts have rated the stock with a Buy rating, eight have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, Phreesia currently has an average rating of “Hold” and a consensus price target of $18.71.

View Our Latest Research Report on Phreesia

Insiders Place Their Bets

In other news, General Counsel Allison C. Hoffman sold 6,176 shares of the firm’s stock in a transaction on Monday, April 20th. The stock was sold at an average price of $9.06, for a total value of $55,954.56. Following the completion of the sale, the general counsel owned 157,309 shares of the company’s stock, valued at $1,425,219.54. This trade represents a 3.78% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider David Linetsky sold 8,332 shares of the firm’s stock in a transaction dated Friday, April 10th. The stock was sold at an average price of $8.07, for a total value of $67,239.24. Following the completion of the sale, the insider directly owned 224,056 shares of the company’s stock, valued at approximately $1,808,131.92. This represents a 3.59% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last 90 days, insiders have sold 50,493 shares of company stock worth $461,983. 5.20% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Phreesia

A number of institutional investors and hedge funds have recently modified their holdings of PHR. Essential Partners LLC lifted its stake in Phreesia by 2,016.6% during the 1st quarter. Essential Partners LLC now owns 9,313 shares of the company’s stock valued at $78,000 after acquiring an additional 8,873 shares during the period. Bank of America Corp DE boosted its stake in shares of Phreesia by 142.6% during the 1st quarter. Bank of America Corp DE now owns 1,001,057 shares of the company’s stock worth $8,389,000 after acquiring an additional 588,444 shares in the last quarter. Amundi acquired a new stake in Phreesia in the first quarter valued at approximately $401,000. EverSource Wealth Advisors LLC grew its stake in Phreesia by 1,119.8% in the 1st quarter. EverSource Wealth Advisors LLC now owns 3,269 shares of the company’s stock valued at $27,000 after acquiring an additional 3,001 shares during the period. Finally, Quantinno Capital Management LP acquired a new stake in shares of Phreesia in the first quarter valued at about $586,000. Institutional investors and hedge funds own 92.10% of the company’s stock.

Phreesia Trading Up 6.7%

The company has a 50 day simple moving average of $9.53 and a 200 day simple moving average of $13.69. The company has a debt-to-equity ratio of 0.41, a quick ratio of 1.53 and a current ratio of 1.53. The company has a market capitalization of $601.83 million, a PE ratio of 325.00 and a beta of 0.89.

About Phreesia

(Get Free Report)

Phreesia, Inc (NYSE: PHR) is a provider of patient intake management solutions designed to streamline front-office workflows for healthcare organizations. The company’s cloud-based platform digitizes patient registration, appointment scheduling, insurance verification, consent documentation and payment collection through touchscreen kiosks, tablets and mobile devices. By replacing paper forms and manual processes, Phreesia enhances data accuracy, reduces administrative burden and improves the patient experience.

Founded in 2000 by Chaim Indig and headquartered in Burlington, Massachusetts, Phreesia offers a modular software suite that integrates with electronic medical record (EMR) and practice management systems.